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Figure 1 Germline mutations in BRCA1 and BRCA2, and in-
heritance of BRCA1 mutation. A, left panel, DNA sequence of a seg-
ment of exon 11 of BRCA1 showing 3888delGAmutation in proband,
as compared with wild-type sequence (lanes WT).A, right panel,DNA
sequence of part of exon 11 of BRCA2 showing 6174delT mutation
in the proband and her father, contrasted with the wild-type sequence
of the mother. B, left panel, DNA sequences of the separate, cloned
alleles showingBRCA1 3888delGAmutation present on paternal allele
(allele 1), with wild-type sequence at 1186. B, right panel, wild-type
BRCA1 sequence of the maternal allele (allele 2) at 3888, with the
1186ArG polymorphism. BRCA1 was sequenced as described else-
where (Southey et al. 1998), and the primers used to sequence BRCA2
have been described in the Breast Cancer Information Core. Separation
of the proband’s BRCA1 alleles was achieved by cloning a purified
PCR-amplified 2.9-kb fragment containing the 1186 polymorphism
and the 3888 deletion Bluescript (Stratagene).
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De Novo BRCA1 Mutation in a Patient with Breast
Cancer and an Inherited BRCA2 Mutation
To the Editor:
Individuals with an inherited mutation in both of the
breast/ovarian cancer–susceptibility genes, BRCA1 and
BRCA2, are rarely described (Ramus et al. 1997; Liede
et al. 1998). Despite the large number of variants iden-
tified in these genes, there are, in the Breast Cancer In-
formation Core, no published reports of de novo mu-
tations.
During the course of the Australian Breast Cancer
Family Study, a population-based study of breast cancer
occurring in women at age !40 years (McCredie et al.
1998; Southey et al. 1998, 1999), we identified a pro-
band who developed high-grade breast cancer with ax-
illary nodal metastases. Her father developed prostate
carcinoma during his early 50s. Her mother had no his-
tory of cancer. The studies outlined below were per-
formed with informed consent from the individuals and
were approved by the Peter MacCallum Cancer Insti-
tute’s review board.
The proband’s leukocyte-derived DNA revealed two
germline protein-truncating mutations: one in exon 11
of BRCA2 (6174delT) and a second in exon 11 of
BRCA1 (3888delGA). These mutations were identified
by the protein-truncation test and by manual DNA se-
quencing in our laboratory (fig. 1A), and were con-
firmed, after collection of a further blood sample, by
heteroduplex analysis in an outside laboratory (data not
shown). The 6174delT BRCA2 mutation has been re-
ported frequently in individuals of Jewish descent (Neu-
hausen et al. 1996); however, there was no known Jewish
ancestry in this family. The 3888delGA BRCA1 muta-
tion has not been reported before by the Breast Cancer
Information Core. The father of the proband carried
only the 6174delT BRCA2 mutation (fig. 1A), and nei-
ther parent carried the 3888delGA BRCA1 mutation.
The proband’s brother was unavailable for testing. DNA
fingerprinting at five informative microsatellite loci sup-
ported the genetic relatedness of the parents’ and pro-
band’s DNA samples (data not shown).
The absence of a germline 3888delGA BRCA1 mu-
tation in either parent indicated that this variant could
represent a de novo alteration that occurred during pa-
rental germ-cell gametogenesis. We evaluated this pos-
sibility by utilizing a heterozygous polymorphism at nu-
cleotide 1186 (1186 ArG) in the proband’s BRCA1
exon 11. The proband’s BRCA1 exon 11 alleles were
separated by cloning, and then were sequenced. The
1186 ArG polymorphism was present on her wild type
3888 allele and in her mother’s germline but was not
present in her father’s germline (fig. 1A). These data
indicate that the BRCA1 3888delGA mutation was on
the father’s allele and further suggest that this mutation
arose as a de novo event in a testicular germ cell.
The presence, in the proband, of heterozygous germ-
line mutations in BRCA1 and BRCA2 raised the ques-
tion of whether dysfunction of both these genes was
involved in the development of her breast carcinoma.
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Figure 2 LOH analysis. Left panel, Loss of the maternally in-
herited (wild-type) BRCA2 allele at the marker D13S290, in ductal
carcinoma in situ (lanes DCIS), invasive and metastatic carcinoma
from the proband. Right panel, Absence of LOH at the intragenic
BRCA1marker D17S855 in DCIS and in invasive carcinoma.NoDNA
PCR control lanes are shown. DNA was microdissected from archival
tumor samples, was subjected to proteinase K digestion, and was an-
alyzed with standard PCR-based microsatellite-analysis protocols em-
ploying published primer sequences for the markers D13S290 and
D17S855 (Simard et al. 1994).
Loss of heterozygosity (LOH) studies performed on mi-
crodissected archival breast-cancer tissue demonstrated
consistent LOH of the maternal (wild type) allele at the
BRCA2-flanking markers D13S260 and D13S290, in
multiple independently dissected areas of invasive ductal
carcinoma. Loss of the maternal allele was also seen in
three adjacent axillary-lymph-node metastases and in
multiple apparently separate foci of high-grade ductal
carcinoma in situ, a preinvasive lesion (fig. 2). These data
are consistent with clonal expansion and dominance of
cells that harbor dysfunction of both alleles of BRCA2,
through multiple phases of malignant progression. In
contrast, evaluation of identical microdissected foci at
the intragenic BRCA1 marker D17S855 showed that
both alleles were retained, suggesting that LOH-induced
inactivation of the second BRCA1 allele was not selected
for during carcinogenesis (fig. 2).
Interestingly, the sequence adjacent to theBRCA1mu-
tation—AGAGGAGAAT (where GA constitutes the de-
leted doublet) is similar to that adjacent to the BRCA2
6174delT mutation—AGTGGAAAAT (where T de-
notes the deleted nucleotide). Although this similarity
could be due to chance, it is also possible that these
sequences are problematic for the germ-cell DNA-rep-
lication machinery and that they are thus prone to mu-
tation. In support of this, haplotype studies suggest that
the 6174delT BRCA2 mutation has arisen on multiple
separate occasions in individuals of varying ethnic ori-
gins (Berman et al. 1996). In an attempt to define a
possible common mechanism underlying the develop-
ment of these twomutations, we used themfold software
of M. Zuker to evaluate the areas of sequence similarity,
together with 100 bp of their respective wild-type
BRCA1- and BRCA2-flanking regions, for their ability
to form secondary structures. The segments of both
genes preferentially formed consistent hairpin loops aris-
ing from unpaired nucleotides at a wide range of bond
energies under physiological conditions. Moreover, in
each case, the deleted bases lay !2 bp from an unpaired
sequence. It is therefore possible that these frameshift
mutations occurred because of deletion of nucleotides
adjacent to unpaired DNA sequences arising in these
quasipalindromic regions. Frameshift mutations occur-
ring in quasipalindromic sequences have been well char-
acterized in Escherichia coli (De Boer and Ripley 1984;
Rosche et al. 1998) and have been suggested as a basis
of the deletion mutations seen in several human genes
(Cooper and Krawczak 1993, pp. 185–188).
There is a further potential explanation for the oc-
currence of the two mutations occurring in this case:
BRCA1 and BRCA2 have been implicated in the main-
tenance of genomic integrity (Rajan et al. 1996; Connor
et al. 1997; Scully et al. 1997; Bertwistle and Ashworth
1998; Chen et al. 1998; Marmorstein et al. 1998; Patel
et al. 1998). Moreover, in the mouse testes, Brca1 and
Brca2 are expressed in the mitotic spermatogonia as well
as in meiotic spermatocytes (Blackshear et al. 1998).
Therefore, the presence, in the father, of one mutated
BRCA2 allele in developing germ cells could confer a
dosage insufficiency and thus result in a generally in-
creased genomic mutation rate. Such an abnormality
could theoretically affect any gene and would thus have
a minimal likelihood of being detected, thus explaining
the absence of reports of supporting evidence. However,
the serendipitous coexistent BRCA1 variant described
here may indicate the need for more-rigorous searches
for de novo germline mutations in other genes arising
in the background of inherited BRCA1/2 mutations.
Further studies using in vitro methods can address
whether sequences such as those described above are
indeed more susceptible to mutation, whether BRCA2
haploinsufficiency results in an increased mutation rate,
and whether these two mutation mechanisms could dis-
play synergistic effects. This case is, to our knowledge,
the first reported example of a de novo mutation arising
in BRCA1, and it suggests a potential mechanism un-
derlying the development of recurrent germline muta-
tions occurring in association with specific sequences.
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